Edition:
United Kingdom

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

0.74USD
15 Feb 2019
Change (% chg)

$0.05 (+6.86%)
Prev Close
$0.69
Open
$0.70
Day's High
$0.75
Day's Low
$0.69
Volume
199,322
Avg. Vol
105,929
52-wk High
$2.55
52-wk Low
$0.48

Latest Key Developments (Source: Significant Developments)

Durect Says Sandoz Is Terminating Development, Commercialization Agreement With Co
Monday, 7 Jan 2019 

Jan 7 (Reuters) - DURECT Corp ::DURECT - RECEIVED WRITTEN NOTICE FROM SANDOZ THAT EFFECTIVE JAN 27, SANDOZ IS TERMINATING DEVELOPMENT & COMMERCIALIZATION AGREEMENT, DATED MAY 5, 2017.DURECT - SANDOZ AG WILL BE RETURNING EXCLUSIVE COMMERCIALIZATION RIGHTS TO DEVELOP AND MARKET POSIMIR IN U.S..DURECT - PARTIES ARE IN DISPUTE WITH REGARD TO SANDOZ AG'S OBLIGATION TO PAY TERMINATION FEE TO CO.DURECT - RELATING TO DISPUTE WITH SANDOZ, INITIATED FORMAL DISPUTE RESOLUTION PROCESS RELATED TO TERMINATION FEE.  Full Article

DURECT Corporation Provides Corporate Update
Monday, 7 Jan 2019 

Jan 7 (Reuters) - DURECT Corp ::DURECT CORPORATION PROVIDES CORPORATE UPDATE.DURECT CORP - EXPECTS TO BEGIN ENROLLING PATIENTS FOR NEW CLINICAL TRIAL OF ORALLY-ADMINISTERED DUR-928 IN NASH PATIENTS IN Q1 2019.DURECT CORP - EXPECTS TO ANNOUNCE INITIAL DATA FROM NEW CLINICAL TRIAL OF ORALLY-ADMINISTERED DUR-928 IN NASH PATIENTS IN SECOND HALF OF 2019.DURECT - REITERATES PRIOR GUIDANCE THAT PSORIASIS TRIAL IS ON TRACK TO BEGIN DOSING THIS QUARTER WITH TOP LINE DATA EXPECTED IN H2 2019.  Full Article

Durect Corp - David R. Hoffmann Will Assume Role Of Chairman Of Board
Monday, 17 Dec 2018 

DURECT Corp ::DURECT CORPORATION ANNOUNCES RETIREMENT OF DR. FELIX THEEUWES AS CHAIRMAN OF THE BOARD AND DISTINGUISHED SCIENTIST.DURECT CORP - DAVID R. HOFFMANN WILL ASSUME ROLE OF CHAIRMAN OF BOARD.DURECT CORP - BOARD OF DIRECTORS HAS INITIATED A SEARCH FOR AN ADDITIONAL INDEPENDENT BOARD MEMBER.  Full Article

DURECT Announces Receipt Of $5 Mln Milestone Payment From Indivior
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - DURECT Corp ::DURECT ANNOUNCES RECEIPT OF $5 MILLION MILESTONE PAYMENT FROM INDIVIOR.DURECT - PAYMENT TRIGGERED BY INDIVIOR'S APPROVAL OF NEW DRUG APPLICATION FOR PERSERIS (RISPERIDONE) IN JULY 2018.  Full Article

Durect Corp Files For Mixed Shelf Of Upto $175 Million
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - DURECT Corp ::DURECT CORP FILES FOR MIXED SHELF OF UPTO $175 MILLION - SEC FILING.  Full Article

Durect Corp Reports Q2 Loss Per Share Of $0.04
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - DURECT Corp ::ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $3.4 MILLION VERSUS I/B/E/S VIEW $3.7 MILLION.QTRLY LOSS PER SHARE $0.04.  Full Article

Durect Announces FDA Approval Of Indivior's Perseris™ (Risperidone) Extended-Release Injectable Suspension
Monday, 30 Jul 2018 

July 30 (Reuters) - DURECT Corp ::DURECT ANNOUNCES FDA APPROVAL OF INDIVIOR'S PERSERIS™ (RISPERIDONE) EXTENDED-RELEASE INJECTABLE SUSPENSION FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS.  Full Article

Durect Announces Amendment To Licensing Agreement With Sandoz
Wednesday, 9 May 2018 

May 9 (Reuters) - DURECT Corp ::DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE).DURECT CORP - DURECT IS NOW ELIGIBLE FOR UP TO $30 MILLION IN MILESTONE PAYMENTS BASED ON NDA APPROVAL.DURECT CORP - EACH PARTY, PURSUANT TO AMENDMENT, IS ALSO PERMITTED TO DEVELOP OR COMMERCIALIZE COMPETING PRODUCTS.DURECT CORP - PURSUANT TO AMENDED AGREEMENT, DURECT REMAINS ELIGIBLE FOR UP TO AN ADDITIONAL $230 MILLION IN SALES-BASED MILESTONES.DURECT - PURSUANT TO AMENDED AGREEMENT, THERE IS NEW TERMINATION FEE PAYABLE TO DURECT IN EVENT THAT SANDOZ TERMINATES AGREEMENT FOR CONVENIENCE.DURECT CORP - AMENDMENT ALSO INCLUDES MODIFICATIONS TO DURECT'S DEVELOPMENT OBLIGATIONS AND TO BOTH PARTIES' TERMINATION PROVISIONS.DURECT CORP - DURECT HAS RIGHT TO TERMINATE FOR CONVENIENCE PRIOR TO NDA APPROVAL.  Full Article

Durect reports Q3 earnings per share of ‍$0.04​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Durect Corp :Durect Corporation announces third quarter 2017 financial results and provides corporate update.Q3 revenue $20.7 million.Q3 revenue view $3.7 million -- Thomson Reuters I/B/E/S.Quarterly earnings per share ‍$0.04​.  Full Article

Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint
Thursday, 19 Oct 2017 

Oct 20 (Reuters) - Durect Corp :Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint.Durect Corp - ‍phase 3 clinical trial for Posimir(®) (saber(®)-bupivacaine), did not meet its primary efficacy endpoint​.Durect Corp - results from phase 3 clinical trial for Posimir​ trended in favor of Posimir versus comparator, but did not achieve statistical significance.  Full Article

Swiss stocks - Factors to watch on Tuesday, Jan. 8

ZURICH/BERLIN, Jan 8 The Swiss blue-chip SMI was seen opening 0.90 lower at 8,566 points on Tuesday, according to premarket indications by bank Julius Baer .